Acute Coronary Syndromes
SCAAR: Could cheap heparin replace pricy bivalirudin in PCI for non-STE-ACS?
1 COMMENT - May 21, 2013 13:50 EDT
Investigators for a new SCAAR registry analysis point out that bivalirudin has been widely studied only against a combination of GP IIb/IIIa inhibition and heparin, but that heparin alone is cheaper and yielded similar 30-day mortality rates in this patient group.

Paris, France - A new analysis from Sweden's SCAAR database is calling into question the use of bivalirudin (Angiomax, the Medicines Company) in the setting of PCI for patients with non-ST-elevation ACS.

Presenting the results here at EuroPCR 2013, Dr Oskar Angeras (Sahlgrenska University Hospital, Gothenburg, Sweden) said that he and his colleagues are pushing forward with a randomized controlled trial to confirm the registry findings. But in the meantime, his hospital has already switched from bivalirudin to heparin.
Read full article »

Interventional/Surgery
Elective PCI ischemic preconditioning: Clinical gains durable up to six years
May 24, 2013 14:01 EDT

Acute Coronary Syndromes
Rivaroxaban approved for ACS secondary prevention in Europe
May 24, 2013 13:15 EDT

Imaging
RIPCORD: FFR during diagnostic angio may radically alter treatment plans
May 23, 2013 12:15 EDT

Interventional/Surgery
SOURCE XT one-year numbers may be best TAVR survival data so far
May 22, 2013 11:30 EDT

Interventional/Surgery
Girl trouble: Rising tide of STEMI in young women "clearly not acceptable"
May 22, 2013 08:10 EDT

Interventional/Surgery
BIOFLOW II: New bioabsorbable-polymer/thin-strut sirolimus stent shows promise
May 21, 2013 11:30 EDT

From the blogsView all »
Cutting-edge dialogues with
Drs Tim Gardner and Mat Williams
Mandrola
Sapien TAVR, CV surgeon report cards, and ethical responsibilities of cardiologists
Jun 18, 2012 10:15 EDT
Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
Healthcare reform and cardiology: An even-keeled update
Healthcare reform and cardiology: An even-keeled update
May 2, 2013 08:45 EDT
Breaking embargo: PREVAIL and how we publish data from clinical trials
Breaking embargo: PREVAIL and how we publish data from clinical trials
Apr 12, 2013 16:33 EDT
ACC 2013 research highlights: A slideshow presentation
ACC 2013 research highlights: A slideshow presentation
4 COMMENTS - Mar 19, 2013 10:00 EDT
View all »Collections
heartwire collections groups our most compelling cardiology news coverage and editorial content by popular themes. Find everything on a single topic, in one place, with one click.
Erectile dysfunction and CHD
Years ago, Viagra made the unexpected transition from hypertension and angina drug...
Antiplatelet up-and-comers
The quest for ever-more effective drugs to decrease platelet aggregation and reduce the...
The Myxo ring mix-up
In 2008, a heartwire investigation reported on a mitral annuloplasty ring, invented by...
Clopidogrel and PPIs
Proton-pump inhibitors have been prescribed to reduce the gastrointestinal risks of...
Pondering prasugrel
The much-anticipated antiplatelet agent gained FDA approval on the basis of the pivotal...
Case studies (view all)
Mitral-valve repair in patients with hypertrophic obstructive cardiomyopathy and severe mitral anomalies
Oct 22, 2010 14:30 EDT
Resource Center (view all)

What's New